

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|---|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| During the scoping process, stakeholders noted: | |
| <ul style="list-style-type: none">• EGFR exon 20 insertion mutations are more common in women and in people of Asian heritage• There are concerns that lung cancer and the symptoms of lung cancer are associated with stigma, particularly in Asian communities, which could contribute to diagnosis or treatment delaying behaviour. | |
| The committee considered these issues, and concluded that there were no equalities issues that could be addressed in this appraisal. | |

- | | |
|----|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No | |

| | |
|--------------------|--|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No | |
| 4. | Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No | |
| 5. | Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No | |
| 6. | Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| No | |
| 7. | Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where? |
| Yes – section 3.21 | |

Approved by Associate Director (name): Ian Watson

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

Issue date: February 2025

Date: 27 February 2025